Federal Court grants summary judgment based on product identification to Firm client Novartis Pharmaceuticals Corporation.
news | September 29, 2008
On September 29, 2008, Chief Judge Todd J. Campbell of the United States District Court for the Middle District of Tennessee granted summary judgment to Firm client, Novartis Pharmaceuticals Corporation (NPC), in a lawsuit alleging that the prescription medication Aredia® caused osteonecrosis of the jaw. In re: Aredia and Zometa Products Liability Litigation, No. 3:06-MD-1760, slip op. (M.D. Tenn. Sept. 29, 2008). Chief Judge Campbell found that NPC had submitted evidence that plaintiff had only been exposed to generic pamidronate, not NPC’s product Aredia®. Plaintiff had not opposed NPC’s motion for summary judgment. Accordingly, Chief Judge Campbell granted summary judgment for NPC.
The MDL coordinating cases involving Aredia® and/or Zometa® was assigned to Chief Judge Campbell by the Judicial Panel on Multidistrict Litigation on April 18, 2006. Hollingsworth LLP is counsel to Novartis Pharmaceuticals Corporation.